Acorda halts heart failure trial; AstraZeneca set to make brodalumab decision;

@FierceBiotech: ICYMI yesterday: Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Article | Follow @FierceBiotech

@JohnCFierce: Top #ASCO15 story for @FierceBiotech: Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer. Story | Follow @JohnCFierce

@DamianFierce: Kinda feels like $JUNO Googled "CAR-T" and is gradually buying the whole first page of results. Release | Story | Follow @DamianFierce

> Acorda Therapeutics ($ACOR) has paused a Phase Ib trial on the heart failure treatment cimaglermin alfa after observing kidney damage in some patients. More

> AstraZeneca ($AZN) plans to decide in a "few weeks" whether to carry on with brodalumab, an investigational psoriasis treatment whose ties to suicidal thoughts led partner Amgen ($AMGN) to walk away from the project last month. News

> Novartis' ($NVS) anti-inflammatory treatment secukinumab succeeded in a Phase III study in ankylosing spondylitis, the company's next desired indication after winning approval in psoriasis. Story

Medical Device News

@FierceMedDev: ICYMI: Fierce exclusive: Zimmer to cut staff, close its dental headquarters following $13B merger with Biomet. Report | Follow @FierceMedDev

@VarunSaxena2: Hospitals tell feds that they can do more to support unique device ID. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Otsuka faces the music for generic Abilify, loses battle with  | Follow @EmilyWFierce

> Prenatal Dx player Natera looks to do an up to $100M IPO to expand, move into liquid biopsy. More

> Israeli startup unveils cloud-based mobile fetal monitor. Article

Pharma News

@FiercePharma: ICYMI: Look for orphan drugs to keep fueling M&A, Moody's says. Report | Follow @FiercePharma

@CarlyHFierce: Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Mylan deal target Perrigo bags GSK, Novartis consumer meds. News

> Mylan challenges Teva to put up a bid--or shut up and let it buy Perrigo. Report

Drug Delivery News

> NeuroVive's cardiology candidate fails to meet its endpoint. Item

> Cedars-Sinai team develops delivery-Dx combo nanomed for brain cancer. More

> Reassessment of trial data at ASCO to benefit Sirtex's cancer-fighting microspheres. Report

> Novartis partners with 'robotic' pillmaker in oral biologic race. Story

> FDA approves Lilly's reformulated insulin to foster patient convenience. Article

Pharma Manufacturing News

> Myanmar Pharma plans $30M upgrade to compete with Indian imports. Item

> South Korea's Green Cross building $240M plasma plant in Canada. More

> Hospira again shipping ketorolac but U.S. faces many drug shortages. Story

> Wockhardt looks to get banned plants back online in 2016. Article

> Sources: Cipla, Lupin bid on UCB's Kremers Urban. Report

Pharma Asia News

> Leading Japan drug firms team up with AZ on parasitic disease research. News

> SK Biopharmaceuticals says Jazz-led sleep disorder PhIII candidate on the cards. Report

> Taiwan recalls Y.F. Chemical sodium chloride products on new contamination events. Article

> Cipla, Lupin in UCB U.S. generics bid as India-linked M&A heats up. More

> Novartis India gets reprieve from NPPA on fine for over-pricing drug. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.